High expression of AlkB homolog 5 suppresses the progression of non-small cell lung cancer by facilitating ferroptosis through m6A demethylation of SLC7A11

  • 0Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.

|

|

Summary

This summary is machine-generated.

Upregulating AlkB homolog 5 (ALKBH5) in non-small cell lung cancer (NSCLC) reduces tumor growth. ALKBH5 promotes ferroptosis by decreasing m6A modification of SLC7A11, inhibiting NSCLC progression.

Area Of Science

  • Oncology
  • Molecular Biology
  • Epigenetics

Background

  • Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality.
  • AlkB homolog 5 (ALKBH5) is recognized for its tumor-suppressive functions in various cancers.
  • The specific role of ALKBH5 in NSCLC pathogenesis remains to be fully elucidated.

Purpose Of The Study

  • To investigate the functional role of ALKBH5 in the development of non-small cell lung cancer.
  • To explore the underlying molecular mechanisms, including the interaction between ALKBH5, SLC7A11, and ferroptosis in NSCLC.

Main Methods

  • Expression analysis of ALKBH5 in NSCLC using TCGA database and cell lines.
  • Investigated the effects of ALKBH5 and SLC7A11 modulation on NSCLC cell behaviors (viability, apoptosis, migration, invasion).
  • Assessed ferroptosis markers, N6-methyladenosine (m6A) modification, and in vivo tumor growth.

Main Results

  • ALKBH5 was found to be downregulated in NSCLC.
  • ALKBH5 overexpression suppressed NSCLC cell proliferation, migration, and invasion while enhancing apoptosis.
  • ALKBH5 inhibited SLC7A11 expression via reduced m6A modification, promoting ferroptosis and suppressing tumor growth in vivo.

Conclusions

  • ALKBH5 upregulation inhibits NSCLC progression by promoting ferroptosis.
  • This occurs through the downregulation of SLC7A11 transcription mediated by decreased m6A modification.
  • ALKBH5 acts as a tumor suppressor in NSCLC by modulating ferroptosis pathways.